Pembrolizumab

Category: biologic

Aliases: Keytruda

Pharmacological Mechanism

Humanised IgG4 mAb binding PD-1 on T cells → blocks PD-L1/L2 inhibitory signals → releases 'braked' T cells to attack tumour. Tumour-agnostic approval for MSI-high tumours (2017) was an FDA first. ~30+ cancer indications across every anatomic site. Revolutionised oncology.

Half-Life (t½)

IV: 552h

Dosing Guidelines

• IV: Typical 200mg (Range: 200 - 200 mg)

Target Organ Systems

• immune-hematologic